Rx Product News (September 2017)

SEPTEMBER 25, 2017

VOSEVI
MARKETED BY:
Gilead Sciences
INDICATION: The FDA approved Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) to treat chronic hepatitis C virus infection genotypes 1-6 in patients without cirrhosis or with mild cirrhosis.
DOSAGE FORM: Tablets: 400-mg sofosbuvir, 100- mg velpatasvir, and 100-mg voxilaprevir
FOR MORE INFORMATION: gilead.com


IDHIFA
MARKETED BY:
Celgene
INDICATION: The FDA has approved Idhifa (enasidenib) to treat adult patients with relapsed or refractory acute myeloid leukemia who have an isocitrate dehydrogenase- 2 gene mutation.
DOSAGE FORM: Tablets: 50 mg or 100 mg
FOR MORE INFORMATION: Celgene.com


TREMFYA
MARKETED BY:
Janssen Biotech
INDICATION: The FDA has approved Tremfya (guselkumab) to treat adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
DOSAGE FORM: Injection: 100 mg/mL
FOR MORE INFORMATION: janssen.com


BLINCYTO
MARKETED BY:
Amgen
INDICATION: The FDA has approved the supplemental Biologics License Application for Blincyto (blinatumomab) to include overall survival data from the phase 3 TOWER study, converting Blincyto’s accelerated approval to a full approval. The approval expands the indication of Blincyto to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children.
DOSAGE FORM: Injection: 35 mcg
FOR MORE INFORMATION: amgen.com

SHARE THIS SHARE THIS
0
Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.